AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29309971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive challenge (silent backward counting in steps of seven)
Number of subjects: 19
Study 29309971 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual perturbations (eyes open, eyes closed)
Number of subjects: 19
Study 29309971 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface perturbations (stable support, foam support)
Number of subjects: 19
Study 29309971 — intervention group
Group type: COMPARATOR
Intervention: Double-leg stance tests under challenging conditions
Number of subjects: 19
Study 25147574 — intervention group
Group type: EXPERIMENTAL
Intervention: Real auricular point acupressure (APA) treatment
Number of subjects: 37
Study 25147574 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 37
Study 22315389 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-assisted strategy
Number of subjects: 39158
Study 22315389 — intervention group
Group type: COMPARATOR
Intervention: Nurse-assisted strategy
Number of subjects: 39158
Study 20961348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic Skin Flattening (PSF)
Number of subjects: 12
Study 20961348 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Cooling Device (DCD)
Number of subjects: 12
Study 18485150 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 129314
Study 18485150 — intervention group
Group type: COMPARATOR
Intervention: Single agent therapy
Number of subjects: 129314
Study 16305291 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg twice/day for 14 days
Number of subjects: 14
Study 14644211 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) lenses (31 Pharmacia/Upjohn 811 B and 25 Domilens Flex 60)
Number of subjects: 138
Study 14644211 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethylmethacrylate/methylmethacrylate (HEMA/MMA) lenses (25 Technomed, Memory Lens)
Number of subjects: 138
Study 14644211 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone lenses (32 Allergan Si40)
Number of subjects: 138
Study 14644211 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic lenses (25 Storz Hydroview)
Number of subjects: 138
Study 14644211 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery with intraocular lens implantation
Number of subjects: 138
Study 10929899 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy subjects
Number of subjects: 0
Study 10929899 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operated GORD patients
Number of subjects: 0
Study 10929899 — intervention group
Group type: COMPARATOR
Intervention: Operated GORD patients
Number of subjects: 0
Study 10929899 — intervention group
Group type: COMPARATOR
Intervention: Operated patients
Number of subjects: 0
Study 10929899 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operated and operated cases
Number of subjects: 0
Study 8873108 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine (0.429 mg/kg)
Number of subjects: 45
Study 8873108 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (control)
Number of subjects: 45
Study 8873108 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine (0.214, 0.286, 0.357, and 0.429 mg/kg)
Number of subjects: 45
Study 1379740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin/cisplatin before radiotherapy
Number of subjects: 97
Study 1379740 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy
Number of subjects: 97
Study 6506360 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term catheter treatment (1 day)
Number of subjects: 43
Study 6506360 — intervention group
Group type: COMPARATOR
Intervention: Long-term catheter treatment (14 days)
Number of subjects: 43
Study 30717778 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry-based RCTs
Number of subjects: 0
Study 29393194 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (EPZ)
Number of subjects: 1835
Study 29393194 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole (RPZ)
Number of subjects: 1835
Study 29393194 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan-based triple therapy
Number of subjects: 1835
Study 26946726 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Guanyuan (CV 4), Shenshu (BL 23), Zusanli (ST 36)
Number of subjects: 230
Study 26946726 — intervention group
Group type: COMPARATOR
Intervention: Pidotimod 10 mL orally once a day for 90 days
Number of subjects: 230
Study 25253679 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of diabetes management during Ramadan (measured by aggregate scores from three knowledge questions)
Number of subjects: 298
Study 25253679 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to attend a workshop on medication regimen adjustment during Ramadan
Number of subjects: 298
Study 22694242 — intervention group
Group type: EXPERIMENTAL
Intervention: AccuVein AV300 device
Number of subjects: 146
Study 22694242 — intervention group
Group type: COMPARATOR
Intervention: Standard insertion technique
Number of subjects: 146
Study 20179619 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 30
Study 20179619 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% twice daily
Number of subjects: 30
Study 17610043 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 38
Study 17610043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 16234607 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 20
Study 16234607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12039617 — intervention group
Group type: EXPERIMENTAL
Intervention: Levo‐alpha‐acetylmethadol (LAAM) maintenance
Number of subjects: 58
Study 12039617 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 58
Study 9579498 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (bolus dose of 100 microg/kg, followed by continuous infusion of 30 microg x kg(‐1) x h(‐1))
Number of subjects: 24
Study 8624293 — intervention group
Group type: COMPARATOR
Intervention: 20 Gy radiotherapy to initially involved fields (RT-arm)
Number of subjects: 288
Study 8624293 — intervention group
Group type: COMPARATOR
Intervention: 1 X (COPP + ABVD) chemotherapy (CT-arm)
Number of subjects: 288
Study 8624293 — intervention group
Group type: COMPARATOR
Intervention: No consolidation therapy
Number of subjects: 288
Study 2686291 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic prophylaxis
Number of subjects: 0
Study 2686291 — intervention group
Group type: COMPARATOR
Intervention: Control group without antibiotic prophylaxis
Number of subjects: 0
Study 799995 — intervention group
Group type: EXPERIMENTAL
Intervention: halcinonide-neomycin-amphotericin
Number of subjects: 100
Study 799995 — intervention group
Group type: COMPARATOR
Intervention: hydrocortisone-iodochlorhydroxyquin
Number of subjects: 100
Study 799995 — intervention group
Group type: EXPERIMENTAL
Intervention: halcinonide-neomycin-amphotericin cream
Number of subjects: 100
Study 799995 — intervention group
Group type: COMPARATOR
Intervention: hydrocortisone-iodochlorhydroxyquin cream
Number of subjects: 100
Study 31102257 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg q4w
Number of subjects: 1647
Study 31102257 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab 300 mg q6w
Number of subjects: 1647
Study 31102257 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg q2w
Number of subjects: 1647
Study 30417232 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 40
Study 30417232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26883438 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intravenous infusion of ponesimod over 3 hours
Number of subjects: 0
Study 26883438 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral administration of ponesimod
Number of subjects: 0
Study 25791231 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic pulsed current (MPC)
Number of subjects: 44
Study 25791231 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC coupled with plantar fascia‐specific stretching exercises (SE)
Number of subjects: 44
Study 24705568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy and/or contingency management (12-week randomized controlled trial)
Number of subjects: 20
Study 24705568 — intervention group
Group type: COMPARATOR
Intervention: Healthy-comparison group (N=20)
Number of subjects: 20
Study 21482619 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive CD-ROM-based smoking prevention/cessation curriculum (project ASPIRE)
Number of subjects: 1093
Study 18486273 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly vinorelbine chemotherapy (30 mg/m² for 6 weeks)
Number of subjects: 63
Study 17728357 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rhEPO (48,000 IU)
Number of subjects: 8
Study 17728357 — intervention group
Group type: COMPARATOR
Intervention: Low-dose rhEPO (8000 IU)
Number of subjects: 8
Study 17728357 — intervention group
Group type: COMPARATOR
Intervention: Drug-naïve Parkinson patients (48,000 IU)
Number of subjects: 8
Study 15510804 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal pairs
Number of subjects: 98
Study 15510804 — intervention group
Group type: COMPARATOR
Intervention: Banxia Xiexin Tang (Pinellia Decoction for Purging the Stomach‐fire)
Number of subjects: 98
Study 11589674 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (Andropatch 2.5 mg patches, 1-2 patches per day)
Number of subjects: 35
Study 11589674 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 35
Study 9400916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro human insulin (2.0 mU kg(‐1) min(‐1))
Number of subjects: 16
Study 9400916 — intervention group
Group type: COMPARATOR
Intervention: Human soluble insulin (HS) (2.0 mU kg(‐1) min(‐1))
Number of subjects: 16
Study 7950410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperosmolar agent (glucose solution)
Number of subjects: 0
Study 7950410 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine challenge in house dust mite-sensitive subjects
Number of subjects: 0
Study 7950410 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 0
Study 3298379 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg azelastine
Number of subjects: 34
Study 3298379 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg azelastine
Number of subjects: 34
Study 3298379 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg azelastine
Number of subjects: 34
Study 30053681 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wristband applied to the P6 acupoint
Number of subjects: 111
Study 30053681 — intervention group
Group type: COMPARATOR
Intervention: Placebo wristband (without cap)
Number of subjects: 111
Study 30053681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 111
Study 27768797 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP-reducing therapy
Number of subjects: 255
Study 27768797 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 255
Study 24108409 — intervention group
Group type: EXPERIMENTAL
Intervention: vestipitant (GW597599) 15 mg
Number of subjects: 19
Study 24108409 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam 0.75 mg
Number of subjects: 19
Study 24108409 — intervention group
Group type: EXPERIMENTAL
Intervention: vofopitant (GR205171) 25 mg
Number of subjects: 19
Study 24108409 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 22594907 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol/hydrochlorothiazide 5/6.25 mg (R)
Number of subjects: 180
Study 22594907 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/160 mg (E)
Number of subjects: 180
Study 20706173 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein angiography (FA)
Number of subjects: 526
Study 20706173 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonstudy eyes)
Number of subjects: 526
Study 17436336 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation T
Number of subjects: 0
Study 17436336 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation R
Number of subjects: 0
Study 15872125 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron plus placebo (group H-O)
Number of subjects: 460
Study 15872125 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron plus 8 mg dexamethasone (group H-OD)
Number of subjects: 460
Study 15872125 — intervention group
Group type: COMPARATOR
Intervention: None (group L)
Number of subjects: 460
Study 12373420 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg delta(9)-THC
Number of subjects: 15
Study 12373420 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg delta(9)-THC
Number of subjects: 15
Study 12373420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7618731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine 0.125% with epinephrine 1/200,000 (n = 20)
Number of subjects: 40
Study 7618731 — intervention group
Group type: COMPARATOR
Intervention: Saline (n = 20)
Number of subjects: 40
Study 7618731 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bupivacaine and saline)
Number of subjects: 40
Study 2650578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg tid orally)
Number of subjects: 146
Study 2650578 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocoumarol
Number of subjects: 146
Study 2650578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline and Acenocoumarol (combined treatment)
Number of subjects: 146
Study 2650578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 333952 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 19
Study 333952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31116270 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB) using 20 ml of 0.25% levobupivacaine (ACB-L group)
Number of subjects: 79
Study 31116270 — intervention group
Group type: COMPARATOR
Intervention: Periarticular infiltration using 40 ml (0.125 mg) of levobupivacaine (PAI-L group)
Number of subjects: 79
Study 28045766 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 147
Study 28045766 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 147
Study 26677826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic exposure (IHE)
Number of subjects: 14
Study 26677826 — intervention group
Group type: COMPARATOR
Intervention: Normoxic control (CON)
Number of subjects: 14
Study 23244247 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg/day for 7 days/month followed by Lactobacillus casei for 7 days
Number of subjects: 40
Study 23244247 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic followed by short chain fructo-oligosaccharides
Number of subjects: 40
Study 21312349 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 19747021 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed care disease management program (2006)
Number of subjects: 2906
Study 19747021 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous enrollment in health plan (2006)
Number of subjects: 2906
Study 16179396 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTL (n = 5) - 14 h/day in hypoxia (6 nights at 2,500 m and 12 nights at 3,000 m)
Number of subjects: 11
Study 16179396 — intervention group
Group type: COMPARATOR
Intervention: CON (n = 6) - slept in normoxia (1,200 m)
Number of subjects: 11
Study 14569399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic muscle thickness (MT) measurements
Number of subjects: 27
Study 14569399 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression equations using MT and limb length
Number of subjects: 27
Study 14569399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic MT measurement combined with limb length
Number of subjects: 27
Study 14569399 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple equation using MT only
Number of subjects: 27
Study 11412292 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritramide
Number of subjects: 92
Study 11412292 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 92
Study 9737127 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical vein injection of 20 units of oxytocin diluted to 20 ml with normal saline
Number of subjects: 50
Study 9737127 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 20 ml
Number of subjects: 50
Study 8062355 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 400 mg-codeine 25 mg combination (ACC)
Number of subjects: 198
Study 8062355 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg (A)
Number of subjects: 198
Study 8062355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 198
Study 2522062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal leuprolide 1.6 mg/day
Number of subjects: 0
Study 2522062 — intervention group
Group type: COMPARATOR
Intervention: Danazol 800 mg/day
Number of subjects: 0
Study 30617950 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (15 g of prebiotics, 5 g of probiotic powder containing Lactobacillus acidophilus T16, Bifidobacterium bifidum BIA‐6, Bifidobacterium lactis BIA‐6, and Bifidobacterium longum LAF‐5)
Number of subjects: 75
Study 30617950 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (5 g probiotics with 15 g of maltodextrin as placebo)
Number of subjects: 75
Study 30617950 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 g of maltodextrin)
Number of subjects: 75
Study 30617950 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 75
Study 30617950 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 75
Study 30634880 — intervention group
Group type: EXPERIMENTAL
Intervention: Local lidocaine spray (LS)
Number of subjects: 86
Study 30634880 — intervention group
Group type: COMPARATOR
Intervention: Forced coughing (FC)
Number of subjects: 86
Study 28899222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (400 mg per day)
Number of subjects: 1402
Study 28899222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1402
Study 24902822 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 121
Study 24902822 — intervention group
Group type: COMPARATOR
Intervention: Individual adolescent-focused therapy (AFT)
Number of subjects: 121
Study 24113197 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 62
Study 24113197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 24113197 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 62
Study 22051208 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg, single oral dose)
Number of subjects: 41
Study 22051208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 19358862 — intervention group
Group type: EXPERIMENTAL
Intervention: Similar distractors
Number of subjects: 0
Study 19358862 — intervention group
Group type: COMPARATOR
Intervention: Dissimilar distractors
Number of subjects: 0
Study 19358862 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractors with the same colour as the target on the previous trial
Number of subjects: 0
Study 19358862 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus-driven intertrial priming effects
Number of subjects: 0
Study 19358862 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down controlled similarity effects
Number of subjects: 0
Study 16401670 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 360
Study 16401670 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 360
Study 15349687 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechu
Number of subjects: 100
Study 15349687 — intervention group
Group type: COMPARATOR
Intervention: Tripterygium hypoglaucum hutch tablet
Number of subjects: 100
Study 11020002 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha2b interferon (6 MU tiw) plus ribavirin (1000-1200 mg daily) for 12 months
Number of subjects: 50
Study 11020002 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha2b interferon (6 MU tiw) plus ribavirin (1000-1200 mg daily) for 6 months
Number of subjects: 50
Study 11020002 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha2b interferon (6 MU tiw) plus ribavirin (1000-1200 mg daily)
Number of subjects: 50
Study 9287068 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser de-epithelialization
Number of subjects: 5
Study 9287068 — intervention group
Group type: COMPARATOR
Intervention: Reverse bevel incision (Control)
Number of subjects: 5
Study 7829282 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly group therapy session in the aftercare clinic
Number of subjects: 100
Study 7829282 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor continuity in aftercare clinic
Number of subjects: 100
Study 7829282 — intervention group
Group type: COMPARATOR
Intervention: Counselor assigned to inpatient unit
Number of subjects: 100
Study 3065925 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxycillin/clavulanate
Number of subjects: 71
Study 3065925 — intervention group
Group type: COMPARATOR
Intervention: amoxycillin
Number of subjects: 71
Study 31751449 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high-protein (MHP) diet (30% proteins, 30% lipids, and 40% carbohydrates)
Number of subjects: 305
Study 31751449 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet (22% lipids, 18% proteins, and 60% carbohydrates)
Number of subjects: 305
Study 29533729 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mm dental implants
Number of subjects: 96
Study 29533729 — intervention group
Group type: COMPARATOR
Intervention: 10-mm dental implants
Number of subjects: 96
Study 29533729 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal bone levels
Number of subjects: 96